Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

MyCelx opens line of credit to support, sales, marketing and financing

(Sharecast News) - MyCelx Technologies said on Wednesday that it has opened a $0.5m line of credit with TriState Capital Bank to support sales, marketing and project financing as it expanded in the PFAS remediation and produced water treatment markets. The AIM-traded firm said the facility was priced at the one-month SOFR plus a 1.5% margin, with a minimum rate of 2.49%.

As of 15 August, SOFR stood at 4.36%.

Chief executive Connie Mixon personally guaranteed the line at no cost to the company, constituting a related-party transaction under the AIM rules.

MyCelx said its independent directors, after consulting with its nominated adviser, said the terms were fair and reasonable.

"In securing this new line of credit, MyCelx is placing itself in a stronger position to pursue its robust opportunity pipeline and further capitalize on recent successful trials and installations," commented Mixon.

"The line of credit provides flexibility for the company to increase marketing spend and trials while bridging milestone projects to completion."

MyCelx said it saw growing global recognition of its technology and expects targeted marketing to help convert requests for quotations into contracts.

Reporting by Josh White for Sharecast.com.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.